Compare Recursion Pharmaceuticals Inc (RXRX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Charles Schwab Corporation Common Stock — how do they compare? Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B), while Charles Schwab Corporation Common Stock trades at $107.87 (market cap $186.25B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 102.9× Recursion Pharmaceuticals Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SCHW | |
|---|---|---|
Market Cap | $1.81B | $186.25B |
Sector | Health | Financials |
52-Week High | $6.79 | $108.02 |
52-Week Low | $2.84 | $85.35 |
Enterprise Value | $1.33B | — |
Dividend Yield | — | 1.19% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
